Indo Borax's CEO contradicts his own CFO on raw material costs in the same earnings call.
The company is guiding for ₹250 cr in revenue, but the call was marred by three internal contradictions, including a mathematical error on DOT capacity guidance.
What's new
- Q4FY26 revenue grew 25.7% YoY to ₹63.04 cr, with PAT up 41.9% to ₹14.53 cr.
- FY27 revenue guidance is ₹250-260 cr, representing 20-25% growth.
- Management declared a ₹40 per share total dividend, including a special ₹30 dividend from non-core asset sales.
Themes from the call
Demand
Management is confident on domestic demand and sees no concerns on orders, scoping growth to the next few quarters.
Margins
EBITDA margin was 20.4% in Q4, supported by improved realization to ₹127-128/kg and 2-quarter forward hedging on raw materials.
Capacity
Boric acid is running near peak volume capacity, with FY27 growth dependent on debottlenecking to 18,000 MTPA and DOT scaling to 1,500 MTPA.
Guidance watch
- FY27 revenue target of ₹250-260 cr (20-25% growth) through debottlenecking and DOT scale-up.
- EBITDA margin guidance of 20-22% for FY27.
- Boron oxide first production expected in Q2-Q3 FY27.
Risk flags
- CFO and MD gave directly conflicting explanations for margin pressure on the same call.
- MD shifted his explanation for the 25-30% revenue growth driver after being challenged, first attributing it to volume then to price.
- A mathematical error was made quantifying DOT capacity utilization, confusing the volume outlook.
- Specific Q1 guidance was explicitly declined despite optimistic commentary.
Key quotes
-
"The challenging geopolitical conditions led to higher raw material prices and pressure on margins."
— Indo Borax CFO, prepared remarks -
"Right now, there are severe price fluctuations in many chemical products, but we are not one of them. Our fluctuations have been very limited."
— Suresh Kalra, MD & CEO, in Q&A session -
"Volume-wise, we are already at peak capacity for boric acid... On the revenue side, it is a factor of pricing, so I stated it could move 25-30% depending on price realizations."
— Suresh Kalra, MD & CEO
The brief
Indo Borax's earnings call was less about the numbers and more about the credibility of the narrative. The financial results were solid: Q4 revenue grew 25.7% to ₹63.04 cr, driven by price realizations that lifted boric acid to ₹127-128/kg. Management guided for ₹250-260 cr in FY27 revenue, a 20-25% increase. But the path to that target was clouded by three internal contradictions.
First, the CFO blamed margin pressure on higher raw material costs. MD Suresh Kalra then told analysts the opposite: that his company doesn't face significant price swings. Second, Kalra initially said the 25-30% growth would come from existing capacity, implying volume. When pushed, he changed his explanation to price realizations. Third, a basic math error was made in quantifying DOT capacity goals, creating confusion about the actual volume target.
These contradictions matter. The company's growth story relies on debottlenecking, new product scaling, and pricing power. If management can't align on the basic drivers during an earnings call, underwriting the ₹250 cr target becomes harder. The new leadership under Genrock Capital has delivered operational improvements, but the call raised questions about the clarity of its forward plan.
The numbers are fine, but the explanations for them keep changing.